Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ETx 22

Next Previous
Drug Profile

ETx 22

Alternative Names: ETx-22; LY-4101174

Latest Information Update: 05 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergence Therapeutics
  • Developer Eli Lilly and Company
  • Class Amanitins; Antineoplastics; Cyclic peptides; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 02 Jun 2026 Efficacy and adverse events data from a phase I trial in Cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology, 2026 (ASCO-2026)
  • 05 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan, Spain, France, China, Belgium, Australia (IV) (NCT06238479)
  • 05 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT06238479)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top